ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

MBRX Company Profile and Key Details

NASDAQ : MBRX

Moleculin Biotech, Inc.

$0.85

0.02+2.41%

At Close 4:00 PM

66.54

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

MBRX Stock Price Chart

Stock Price Today

Moleculin Biotech, Inc. (MBRX) stock surged +2.41%, trading at $0.85 on NASDAQ, up from the previous close of $0.83. The stock opened at $0.85, fluctuating between $0.80 and $0.88 in the recent session.

Stock Snapshot

0.829

Prev. Close

0.85

Open

11.29M

Market Cap

13.3M

Number of Shares

0.8

Day Low

0.875

Day High

-0.13

P/E Ratio

96.86%

Free Float in %

-6.32

EPS (TTM)

13.01

Book Value

-12.09

Cash Flow per Share

205.38K

Volume

Relevant Articles

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 15, 2025	0.85	0.88	0.80	0.85	195.08K
Apr 14, 2025	0.84	0.88	0.80	0.83	271.09K
Apr 11, 2025	0.79	0.80	0.76	0.80	195.06K
Apr 10, 2025	0.79	0.79	0.70	0.73	142.02K
Apr 09, 2025	0.73	0.81	0.69	0.77	232.91K
Apr 08, 2025	0.79	0.83	0.69	0.74	285.31K
Apr 07, 2025	0.78	0.82	0.76	0.79	263.08K
Apr 04, 2025	0.85	0.85	0.76	0.82	460K
Apr 03, 2025	0.92	0.95	0.85	0.87	332.49K
Apr 02, 2025	0.91	0.97	0.91	0.96	238.92K
Apr 01, 2025	1.00	1.04	0.93	0.96	352.94K
Mar 31, 2025	1.00	1.01	0.92	0.97	350.26K
Mar 28, 2025	1.06	1.06	1.01	1.04	367.87K
Mar 27, 2025	1.08	1.09	1.04	1.05	408.1K
Mar 26, 2025	1.11	1.15	1.06	1.07	563.82K
Mar 25, 2025	1.09	1.32	1.03	1.15	2.84M
Mar 24, 2025	1.11	1.11	1.03	1.06	475.63K
Mar 21, 2025	1.04	1.12	1.03	1.09	520K
Mar 20, 2025	1.05	1.15	1.02	1.09	450.86K
Mar 19, 2025	1.07	1.09	0.99	1.04	596.42K

Contact Details

Houston, TX 77007

United States

Website: https://www.moleculin.comContact: 713 300 5160

About Company

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Frequently Asked Questions

What is the current Moleculin Biotech, Inc. (MBRX) stock price?

Moleculin Biotech, Inc. (NASDAQ: MBRX) stock price is $0.85 in the last trading session. During the trading session, MBRX stock reached the peak price of $0.88 while $0.80 was the lowest point it dropped to. The percentage change in MBRX stock occurred in the recent session was 2.41% while the dollar amount for the price change in MBRX stock was $0.02.

MBRX's industry and sector of operation?

The NASDAQ listed MBRX is part of Biotechnology industry that operates in the broader Healthcare sector. Moleculin Biotech, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MBRX?

Mr. Walter V. Klemp
Founder, Chairman, Pres & Chief Executive Officer
Mr. Jonathan P. Foster CPA
Executive Vice President & Chief Financial Officer
Ms. Jacqueline Northcut
Consultant
Mr. Louis Ploth Jr.
Independent Advisor
Dr. Robert C. Shepard FACP, M.D., F.A.C.P.
Chief Medical Officer of Annamycin
Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D.
European Chief Medical Officer
Dr. John Paul Waymack M.D., Sc.D.
Senior Chief Medical Officer

How MBRX did perform over past 52-week?

MBRX's closing price is 113.32% higher than its 52-week low of $0.40 where as its distance from 52-week high of $5.47 is -84.48%.

How many employees does MBRX have?

Number of MBRX employees currently stands at 17.

Link for MBRX official website?

Official Website of MBRX is: https://www.moleculin.com

How do I contact MBRX?

MBRX could be contacted at phone 713 300 5160 and can also be accessed through its website. MBRX operates from 5300 Memorial Drive, Houston, TX 77007, United States.

How many shares of MBRX are traded daily?

MBRX stock volume for the day was 205.38K shares. The average number of MBRX shares traded daily for last 3 months was 5.74M.

What is the market cap of MBRX currently?

The market value of MBRX currently stands at $11.29M with its latest stock price at $0.85 and 13.3M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	17
Beta	2.2
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology